Geode Capital Management
AVXL icon

Geode Capital Management’s Anavex Life Sciences AVXL Stock Holding History

Geode Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.24M Buy
2,407,473
+219,198
+10% +$649K ﹤0.01% 2800
2026
Q1 		$6.72M Buy
2,188,275
+165,363
+8% +$716K ﹤0.01% 2593
2025
Q4 		$7.2M Sell
2,022,912
-4,415
-0.2% -$27K ﹤0.01% 2569
2025
Q3 		$18M Buy
2,027,327
+7,532
+0.4% +$76.4K ﹤0.01% 2047
2025
Q2 		$18.6M Buy
2,019,795
+54,985
+3% +$469K ﹤0.01% 1999
2025
Q1 		$16.9M Buy
1,964,810
+89,888
+5% +$849K ﹤0.01% 1985
2024
Q4 		$20.1M Sell
1,874,922
-8,277
-0.4% -$63.7K ﹤0.01% 1969
2024
Q3 		$10.7M Buy
1,883,199
+51,946
+3% +$300K ﹤0.01% 2339
2024
Q2 		$7.73M Buy
1,831,253
+118,526
+7% +$479K ﹤0.01% 2482
2024
Q1 		$8.72M Buy
1,712,727
+47,363
+3% +$267K ﹤0.01% 2401
2023
Q4 		$15.5M Buy
1,665,364
+92,396
+6% +$636K ﹤0.01% 2064
2023
Q3 		$10.3M Buy
1,572,968
+30,668
+2% +$244K ﹤0.01% 2249
2023
Q2 		$12.5M Buy
1,542,300
+89,422
+6% +$766K ﹤0.01% 2150
2023
Q1 		$12.5M Buy
1,452,878
+47,414
+3% +$473K ﹤0.01% 2117
2022
Q4 		$13M Buy
1,405,464
+79,536
+6% +$850K ﹤0.01% 2076
2022
Q3 		$13.7M Buy
1,325,928
+13,706
+1% +$145K ﹤0.01% 2016
2022
Q2 		$13.1M Buy
1,312,222
+4,385
+0.3% +$41.5K ﹤0.01% 2062
2022
Q1 		$16.1M Buy
1,307,837
+10,466
+0.8% +$129K ﹤0.01% 2029
2021
Q4 		$22.5M Buy
1,297,371
+99,262
+8% +$1.89M ﹤0.01% 1871
2021
Q3 		$21.5M Buy
1,198,109
+40,537
+4% +$807K ﹤0.01% 1911
2021
Q2 		$26.5M Buy
1,157,572
+121,887
+12% +$1.81M ﹤0.01% 1783
2021
Q1 		$15.5M Buy
1,035,685
+242,093
+31% +$2.64M ﹤0.01% 2040
2020
Q4 		$4.29M Buy
793,592
+42,775
+6% +$225K ﹤0.01% 2681
2020
Q3 		$3.42M Buy
750,817
+30,092
+4% +$130K ﹤0.01% 2602
2020
Q2 		$3.54M Buy
720,725
+3,144
+0.4% +$11.9K ﹤0.01% 2520
2020
Q1 		$2.26M Buy
717,581
+104,462
+17% +$364K ﹤0.01% 2607
2019
Q4 		$1.59M Buy
613,119
+24,271
+4% +$63.7K ﹤0.01% 3105
2019
Q3 		$1.86M Buy
588,848
+37,085
+7% +$107K ﹤0.01% 2976
2019
Q2 		$1.86M Buy
551,763
+222,915
+68% +$692K ﹤0.01% 2997
2019
Q1 		$1M Buy
328,848
+36,900
+13% +$88.1K ﹤0.01% 3162
2018
Q4 		$455K Buy
291,948
+3,687
+1% +$8.37K ﹤0.01% 3408
2018
Q3 		$786K Buy
288,261
+7,156
+3% +$20.2K ﹤0.01% 3315
2018
Q2 		$736K Sell
281,105
-44,482
-14% -$124K ﹤0.01% 3302
2018
Q1 		$898K Buy
325,587
+7,068
+2% +$20K ﹤0.01% 3169
2017
Q4 		$1.02M Buy
318,519
+7,740
+2% +$30.5K ﹤0.01% 3088
2017
Q3 		$1.29M Buy
310,779
+11,297
+4% +$50.2K ﹤0.01% 3004
2017
Q2 		$1.59M Buy
299,482
+22,508
+8% +$130K ﹤0.01% 2865
2017
Q1 		$1.59M Buy
276,974
+39,934
+17% +$206K ﹤0.01% 2783
2016
Q4 		$938K Buy
237,040
+7,075
+3% +$25.2K ﹤0.01% 3024
2016
Q3 		$834K Buy
229,965
+3,677
+2% +$15.5K ﹤0.01% 3034
2016
Q2 		$1.38M Buy
226,288
+46,739
+26% +$226K ﹤0.01% 2722
2016
Q1 		$879K Buy
179,549
+57,572
+47% +$253K ﹤0.01% 2950
2015
Q4 		$679K Buy
+121,977
New +$868K ﹤0.01% 3110

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management's AVXL Position: Q2 2026 in Review

Geode Capital Management increased its Anavex Life Sciences (AVXL) stake by 10% in Q2 2026, buying an estimated $649K and bringing the position to 2,407,473 shares worth $6.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2800.

Geode Capital Management first reported a position in AVXL in Q4 2015 and has held it in 43 quarters since. The position peaked at $26.5M in Q2 2021. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Geode Capital Management held 2,407,473 shares of Anavex Life Sciences worth $6.24M as of Q2 2026.
  • Geode Capital Management bought 219,198 Anavex Life Sciences shares in Q2 2026, an estimated $649K.
  • Anavex Life Sciences made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2800 holding.
  • Geode Capital Management first reported a position in Anavex Life Sciences in Q4 2015 and has held it in 43 quarters since.
  • Geode Capital Management's Anavex Life Sciences position peaked at $26.5M in Q2 2021.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.